Evaluation of Polygenic Risk Scores for a Possible Genetic Basis of the Inverse Association Between Cancer and Cognitive Decline
Rebecca E. Graff, Dorothy M. Chen, Kaitlin N. Swinnerton, Sarah F. Ackley, Monica Ospina‐Romero, Scott C. Zimmerman, Jingxuan Wang, Peter T. Buto et al.. Alzheimer Disease & Associated Disorders, 2025-10-01
Topic: Risk, prevention and care in population studies
Plain-language summary
In UKB, PRS cancer was nominally associated with improved fluid intelligence ( β : 0.12, 95% CI: 0.01-0.22). Twelve variants in PRS cancer , including 7 in the human leukocyte antigen (HLA) complex, were positively associated with fluid intelligence, and 7 were inversely associated ( P <5.8×10 -5 ). PRS cancer and its contributing variants were not associated with cognitive outcomes in HRS. PRS AD was not associated with cancer risk in either study cohort. Though not conclusive, the direction of the association between PRS cancer and fluid intelligence was consistent with our a priori hypothesis that cancer risk variants would decrease cognitive decline. The association pattern with HLA-related variants suggests potential relevance of immune surveillance for the inverse association between dementia and cancer.
What this study adds
Evidence grade: Moderate
A genetic score for cancer risk was nominally associated with better fluid intelligence in one cohort but not associated with cognitive outcomes in another. The findings were not conclusive, and no protective effect against cognitive decline was established.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Graff, R. E., Chen, D. M., Swinnerton, K. N., Ackley, S. F., Ospina‐Romero, M., Zimmerman, S. C., et al. (2025). Evaluation of Polygenic Risk Scores for a Possible Genetic Basis of the Inverse Association Between Cancer and Cognitive Decline. Alzheimer Disease & Associated Disorders. https://doi.org/10.1097/wad.0000000000000696
Vancouver
Graff RE, Chen DM, Swinnerton KN, Ackley SF, Ospina‐Romero M, Zimmerman SC, et al. Evaluation of Polygenic Risk Scores for a Possible Genetic Basis of the Inverse Association Between Cancer and Cognitive Decline. Alzheimer Disease & Associated Disorders. 2025. doi:10.1097/wad.0000000000000696. PMID: 41128446.
BibTeX
@article{graff2025-41128446,
author = {Graff, Rebecca E. and Chen, Dorothy M. and Swinnerton, Kaitlin N. and Ackley, Sarah F. and Ospina‐Romero, Monica and Zimmerman, Scott C. and Wang, Jingxuan and Buto, Peter T. and others},
title = {{Evaluation of Polygenic Risk Scores for a Possible Genetic Basis of the Inverse Association Between Cancer and Cognitive Decline}},
journal = {Alzheimer Disease \& Associated Disorders},
year = {2025},
doi = {10.1097/wad.0000000000000696},
pmid = {41128446},
url = {https://doi.org/10.1097/wad.0000000000000696}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- In UKB, PRS cancer was nominally associated with improved fluid intelligence ( β : 0.12, 95% CI: 0.01-0.22).
- Twelve variants in PRS cancer , including 7 in the human leukocyte antigen (HLA) complex, were positively associated with fluid intelligence, and 7 were inversely associated ( P <5.8×10 -5 ).
- PRS cancer and its contributing variants were not associated with cognitive outcomes in HRS.
- PRS AD was not associated with cancer risk in either study cohort.
- Though not conclusive, the direction of the association between PRS cancer and fluid intelligence was consistent with our a priori hypothesis that cancer risk variants would decrease cognitive decline.
Why it matters
A genetic score for cancer risk was nominally associated with better fluid intelligence in one cohort but not associated with cognitive outcomes in another. The findings were not conclusive, and no protective effect against cognitive decline was established.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthModerate
How this study scored 37/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer Disease & Associated Disorders) |
| Journal's citation record | 1 / 4 | Alzheimer Disease & Associated Disorders: journal h-index 131 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author M. Maria Glymour: h-index 83 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Stanford University: institution h-index 2,684 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41128446) |
| Free to read | 2 / 2 | Free to read |
| Total | 37 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1097/wad.0000000000000696
- PubMed: 41128446
- Original source →
- Free full text: Alzheimer Disease & Associated Disorders →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Genetics from nearby years
Also in Genetics
210 studies in the library are filed under Genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Genetics hub.